Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.49
(-8.8%)
USD 0.49
(-8.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -23.76 Million USD | 3.35% |
| 2022 | -24.59 Million USD | 0.59% |
| 2021 | -24.73 Million USD | -2.18% |
| 2020 | -24.2 Million USD | -27.93% |
| 2019 | -18.92 Million USD | -29.18% |
| 2018 | -14.64 Million USD | 11.25% |
| 2017 | -16.5 Million USD | -99.86% |
| 2016 | -8.25 Million USD | 16.69% |
| 2015 | -9.91 Million USD | 5.29% |
| 2014 | -10.46 Million USD | -181.89% |
| 2013 | -3.71 Million USD | -3098.31% |
| 2012 | -116.07 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.9 Million USD | -0.25% |
| 2024 Q2 | -5.83 Million USD | 1.07% |
| 2023 Q1 | -5.58 Million USD | -1.94% |
| 2023 Q2 | -6.15 Million USD | -10.26% |
| 2023 Q4 | -5.88 Million USD | 4.03% |
| 2023 Q3 | -6.13 Million USD | 0.41% |
| 2023 FY | -23.76 Million USD | 3.35% |
| 2022 Q2 | -5.92 Million USD | 23.27% |
| 2022 Q1 | -7.72 Million USD | -15.02% |
| 2022 FY | -24.59 Million USD | 0.59% |
| 2022 Q4 | -5.47 Million USD | -0.31% |
| 2022 Q3 | -5.46 Million USD | 7.81% |
| 2021 Q3 | -6.87 Million USD | -43.6% |
| 2021 Q4 | -6.71 Million USD | 2.38% |
| 2021 FY | -24.73 Million USD | -2.18% |
| 2021 Q2 | -4.78 Million USD | 24.61% |
| 2021 Q1 | -6.35 Million USD | 2.09% |
| 2020 FY | -24.2 Million USD | -27.93% |
| 2020 Q3 | -5.6 Million USD | 2.81% |
| 2020 Q2 | -5.76 Million USD | 9.15% |
| 2020 Q1 | -6.34 Million USD | -10.65% |
| 2020 Q4 | -6.48 Million USD | -15.78% |
| 2019 Q3 | -4.56 Million USD | -0.9% |
| 2019 Q1 | -4.1 Million USD | 1.52% |
| 2019 FY | -18.92 Million USD | -29.18% |
| 2019 Q4 | -5.73 Million USD | -25.75% |
| 2019 Q2 | -4.52 Million USD | -10.18% |
| 2018 Q4 | -4.16 Million USD | -41.04% |
| 2018 FY | -14.64 Million USD | 11.25% |
| 2018 Q3 | -2.95 Million USD | 13.24% |
| 2018 Q1 | -4.12 Million USD | 11.01% |
| 2018 Q2 | -3.4 Million USD | 17.37% |
| 2017 Q4 | -4.63 Million USD | -35.86% |
| 2017 FY | -16.5 Million USD | -99.86% |
| 2017 Q3 | -3.4 Million USD | 14.28% |
| 2017 Q2 | -3.97 Million USD | 11.39% |
| 2017 Q1 | -4.48 Million USD | -74.99% |
| 2016 Q2 | -1.62 Million USD | 27.59% |
| 2016 Q4 | -2.56 Million USD | -39.74% |
| 2016 Q3 | -1.83 Million USD | -13.26% |
| 2016 Q1 | -2.23 Million USD | 19.58% |
| 2016 FY | -8.25 Million USD | 16.69% |
| 2015 FY | -9.91 Million USD | 5.29% |
| 2015 Q4 | -2.78 Million USD | -28.88% |
| 2015 Q3 | -2.15 Million USD | 10.12% |
| 2015 Q2 | -2.4 Million USD | 6.49% |
| 2015 Q1 | -2.56 Million USD | 22.4% |
| 2014 Q1 | -2.12 Million USD | -18.03% |
| 2014 Q4 | -3.31 Million USD | -27.05% |
| 2014 Q2 | -2.42 Million USD | -13.69% |
| 2014 FY | -10.46 Million USD | -181.89% |
| 2014 Q3 | -2.6 Million USD | -7.64% |
| 2013 Q3 | -1.45 Million USD | -323.18% |
| 2013 Q2 | -343.37 Thousand USD | -206.22% |
| 2013 Q1 | -112.13 Thousand USD | -18.83% |
| 2013 Q4 | -1.8 Million USD | -24.14% |
| 2013 FY | -3.71 Million USD | -3098.31% |
| 2012 FY | -116.07 Thousand USD | 0.0% |
| 2012 Q4 | -94.36 Thousand USD | -935.34% |
| 2012 Q3 | -9114.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 25.536% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -149.695% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 41.878% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 54.226% |
| Azitra, Inc. | -7.61 Million USD | -212.037% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -190.006% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -246.328% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 18.026% |
| CEL-SCI Corporation | -31.47 Million USD | 24.495% |
| iBio, Inc. | -16.63 Million USD | -42.876% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 3.91% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -17.756% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -69.142% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -375.035% |
| NanoViricides, Inc. | -8.51 Million USD | -179.071% |
| Oragenics, Inc. | -20.9 Million USD | -13.686% |
| BiomX Inc. | -27.68 Million USD | 14.156% |
| BiomX Inc. | -27.68 Million USD | 14.156% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 327.208% |
| Palatin Technologies, Inc. | -22.49 Million USD | -5.645% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 43.458% |
| Theriva Biologics, Inc. | -21.43 Million USD | -10.895% |